Geode Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,407,613 shares of SUPN stock, worth $45.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,407,613

Previous 1,306,950 7.7%

Holding current value

$45.2 Million

Previous $44.6 Million 15.54%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$25.99 - $33.85 $2.62 Million - $3.41 Million	100,663 Added 7.7%	1,407,613 $37.7 Million
Q1 2024 May 13, 2024	BUY	$27.11 - $35.17 $1.68 Million - $2.17 Million	61,796 Added 4.96%	1,306,950 $44.6 Million
Q4 2023 Feb 13, 2024	BUY	$22.72 - $29.68 $3.45 Million - $4.51 Million	152,057 Added 13.91%	1,245,154 $36 Million
Q3 2023 Nov 13, 2023	BUY	$27.57 - $32.91 $1.07 Million - $1.28 Million	38,951 Added 3.7%	1,093,097 $30.1 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $498,091 - $644,970	16,653 Added 1.61%	1,054,146 $31.7 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $1.08 Million - $1.3 Million	30,946 Added 3.07%	1,037,493 $37.6 Million
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $1.79 Million - $2.18 Million	57,637 Added 6.07%	1,006,547 $35.9 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $281,249 - $345,920	9,769 Added 1.04%	948,910 $32.1 Million
Q2 2022 Aug 12, 2022	BUY	$25.33 - $34.25 $231,364 - $312,839	9,134 Added 0.98%	939,141 $27.2 Million
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $903,795 - $1.04 Million	-31,701 Reduced 3.3%	930,007 $30.1 Million
Q4 2021 Feb 11, 2022	BUY	$26.37 - $34.22 $334,767 - $434,422	12,695 Added 1.34%	961,708 $28 Million
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $1.02 Million - $1.36 Million	43,322 Added 4.78%	949,013 $25.3 Million
Q2 2021 Aug 13, 2021	BUY	$26.72 - $33.19 $963,710 - $1.2 Million	36,067 Added 4.15%	905,691 $27.9 Million
Q1 2021 May 12, 2021	BUY	$24.15 - $31.45 $1.79 Million - $2.33 Million	74,193 Added 9.33%	869,624 $22.8 Million
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $573,002 - $835,547	32,373 Added 4.24%	795,431 $20 Million
Q3 2020 Nov 13, 2020	SELL	$20.2 - $25.05 $198,949 - $246,717	-9,849 Reduced 1.27%	763,058 $15.9 Million
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $248,898 - $362,497	14,564 Added 1.92%	772,907 $18.4 Million
Q1 2020 May 14, 2020	BUY	$14.45 - $24.69 $620,757 - $1.06 Million	42,959 Added 6.01%	758,343 $13.6 Million
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $404,559 - $591,309	20,299 Added 2.92%	715,384 $17 Million
Q3 2019 Nov 12, 2019	BUY	$25.47 - $33.37 $492,054 - $644,675	19,319 Added 2.86%	695,085 $19.1 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $1.23 Million - $1.59 Million	40,936 Added 6.45%	675,766 $22.4 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $1.53 Million - $1.96 Million	46,571 Added 7.92%	634,830 $22.2 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $1.37 Million - $2.19 Million	44,268 Added 8.14%	588,259 $19.5 Million
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $741,528 - $982,047	17,366 Added 3.3%	543,991 $27.4 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $1.2 Million - $1.62 Million	27,136 Added 5.43%	526,625 $31.5 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $1.29 Million - $1.63 Million	34,749 Added 7.48%	499,489 $22.9 Million
Q4 2017 Feb 13, 2018	BUY	$36.4 - $42.6 $563,799 - $659,831	15,489 Added 3.45%	464,740 $18.5 Million
Q3 2017 Nov 14, 2017	SELL	$36.75 - $49.65 $189,556 - $256,094	-5,158 Reduced 1.14%	449,251 $18 Million
Q2 2017 Aug 14, 2017	BUY	N/A	454,409	454,409 $19.6 Million

Others Institutions Holding SUPN

# of Institutions

255

Shares Held

59.2M

Call Options Held

47.9K

Put Options Held

13.1K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.72B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History